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Abstract 
Introduction:  Intermittent hormone therapy (IHT) was developed to reduce morbidity of 
treating metastatic prostate cancer. Increasingly it is seen as an alternative to “watchful 
waiting” in those who the need for radical treatment is uncertain.  Here pooled phase 2 
data is reviewed to see if this apparent efficacy is supported. Preliminary comparisons 
between the different IHT regimens used are made. Models predicting success of 
treatment are generated. The use of time off treatment to indicate treatment success is 
examined. Possible future trials using this endpoint are suggested. 
Methods:  Data was collated on 1446 patients with adequate data, from 10 phase 2 
studies with more than 50 cases, identified through Pubmed.  
Results:  Patients with localised disease achieved 90% 5yr survival, 29% off hormone 
therapy for over 2 years and 10% hormone resistant in 5 years. This compared to 86%, 
33% and 17% respectively for biochemical recurrence in patients after radical treatment 
and 68%, 16% and 41% for metastatic disease.   
Univariate and multivariate Cox proportional hazard modeling demonstrated that initial 
PSA and PSA nadir were important predictors of time off therapy. 40% of patients with 
localized disease with a pre-treatment PSA less than 10 were off treatment at 2 years 
after <4 months therapy.   
Conclusion:  Initial PSA and PSA nadir enable definition of prostate cancer patients in 
whom it may be safe to avoid radical therapy.  This strategy should be tested in future 
trials against watchful waiting and radical therapy.  
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Introduction 
It has been said of patients with prostate cancer that those who are curable by radical 
prostatectomy don't need to be cured, and those that need to be cured, can't be 
cured[1]. This view first became established in the light of results from the two 
randomized Veterans Administration Collaborative Group (VACURG) studies [2]. These 
were placebo-controlled trials examining the role of endocrine treatment. They were 
initiated following a retrospective analysis of Nesbit’s personal series in the 1950s who 
questioned the value of early treatment [3]. Today 4516 patients have been recruited 
into 5 randomized trials [4-8] and a benefit to immediate treatment is still contentious. 
On close examination, the VACURG trials provide some evidence in favor of immediate 
treatment. The first study with 2000 patients randomized was the largest and because it 
used high dose stilboestrol (5mg), had excess cardiac deaths and showed no 
advantage to early treatment because of these excess deaths. This study, though never 
published formally, led to an attitude of benign neglect developing over the use of early 
hormone treatment. This was despite the second VACURG study (508 patients) which 
used a less toxic dose of stilboestrol (1mg) and demonstrated 9% less deaths with 
immediate treatment. The three subsequent studies have recruited a total of 2107 
patients and have shown a consistent 5% less deaths from immediate treatment, 
though in only the last study [9] was the difference statistically significant.  Even in this 
most recent study, the authors conclude that deferring androgen ablation therapy was 
probably still the better option. This was because a substantial number of patients were 
spared the burden of continuous endocrine treatment. These were patients who would 
be expected to remain asymptomatic and not die of prostate cancer. 
 
Recently Intermittent hormone therapy (IHT, also Intermittent Androgen Suppression 
and Intermittent Androgen Deprivation), initially introduced to reduce morbidity of 
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treating metastatic disease, has emerged as an alternative better tolerated treatment 
option to “watchful waiting” in those who the need for radical treatment is uncertain.  A 
766 case phase three trial comparing three months of IHT with continuous therapy 
demonstrated that IHT, as well as producing equivalent overall survival, allowed 29% of 
those randomized to the IHT arm to remain off treatment for 3 years [10;11].  
The aims of this study are: 
• To compare results of smaller phase two studies with the randomised trial.  
• To develop models predicting success in IHT. 
• To describe features of IHT protocols conferring success 
• To evaluate the use of time off treatment as a surrogate predictor of survival for 
use in future IHT trials. 
 
Methods 
A Pubmed search was undertaken with keywords intermittent hormone/androgen 
ablation, the references from the papers found were checked and authors were 
consulted as to other sources of data.  Ten groups with data pertaining to the use of IHT 
(n>50) were identified [12-21]. Table 1 shows the origin and basic characteristics of the 
patients in each study as well as the IHT protocol characteristics. Individual patient data 
was collected from the authors and collated into a database of 1498 patients. Of these, 
1446 had adequate data for inclusion in our analysis. All patients were hormone naïve 
prior to starting IHT. 
Patient data was grouped into: 
Group 1) Localized disease (N0M0) treated primarily with IHT  
Group 2) PSA recurrence after failed curative attempts with radiotherapy, prostatectomy 
or both, and  
Group 3) Metastatic disease treated with IHT.   
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Data was analyzed using Stata Intercooled 8.0. All durations are the length of time after 
starting hormone therapy. Day 1 is the first day that hormones were given.  Kaplan 
Meier Survival analysis was undertaken. Univariate and multivariate Cox proportional 
hazard models were developed for each of the three groups. A forward stepwise 
procedure was used to develop the multivariate models in Stat 8.0. The variables 
available for addition to the model were initial PSA, type of hormone treatment, duration 
of treatment, PSA nadir, age, T stage, Gleason grade, previous treatment, restart PSA 
threshold and metastatic status. The results of the univariate analysis were used to 
select which variable should be added to the model (see appendices 1 and 2 for 
detailed results of univariate analysis). The variables were dichotomized for further 
analysis about clinically relevant thresholds. The change in chi2 in the multivariate 
results (figure 1 and supplementary table- appendix 3) indicates the proportion of 
variability in outcome explained by the variable. A large change in chi2 indicates that a 
variable is important in predicting the particular outcome. 
Success of treatment was measured according to three factors: 
1. Time spent in clinical remission and off treatment after initial period of androgen 
deprivation. 
2. Time to AIPC (AIPC is defined as two successively rising PSA measurements or 
clinical progression despite hormone therapy.  
3. Overall survival (OS) 
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Results 
Data was collected on 1446 patients. Median age was 71 years. 366 patients had 
proven nodal or metastatic disease at the time of starting IHT. Of the remaining 1080 
with no known metastatic disease, for 517 patients this was the primary treatment. The 
remaining 563 were treated for recurrent disease after failed Radical Prostatectomy 
(RP) radiotherapy (RT) or both. 
Median number of cycles was 2. Median follow up for all patients was 39 months. 
Maximum follow up was 197 months. Median time off treatment for all patients was 15.4 
months. 181 patients developed AIPC. 218 died.  
Overall 29 percent of patients with localized disease were off treatment 2 years after the 
initial period of hormone ablation was complete, 90% were alive at 5 years and 10% 
had become androgen independent (Table 2).  This compares to 33%, 86% and 17% in 
the biochemical recurrence group 2 and 16%, 68% and 41% in group 3.  Table 3 shows 
a summary of the uni-variate analysis (see appendix supplementary tables 6&7 for 
details).  The results of the multivariate modeling are shown in figure 1. Table 4 
demonstrates the association between duration of remission and the other outcome 
measures. Table 5 shows that the duration of remission is not dependent on the level to 
which the PSA is allowed to rise before treatment in restarted. 
 
Discussion 
From the time of the original observation on the use of hormonal manipulation as a 
treatment for prostate cancer[22] and the development of means of medical castration 
there has been controversy over when and for how long medical treatment should be 
administered for. This first emerged in a publication when Nesbit retrospectively 
reviewed a series with early and late hormonal treatment [23]. This led Byar to set up 
The VACURG [24-26] studies demonstrated the excess deaths with high dose 
 7 
oestrogen that negated any benefit from therapy and laid the ground for 30 years of 
negative attitude towards early endocrine therapy.  The concerns about early use of 
continuous therapy persisted throughout the introduction of the LHRH analogues. The 
concerns about early use continued throughout the introduction of maximum androgen 
blockade (MAB) [27]. 
 
The recent study by Studer et al [28] has produced evidence which might reverse this 
negative attitude. However, in demonstrating a minor benefit of early treatment he still 
concluded that this might not be adequate to justify routine early use of continuous 
hormone ablation. This was because of the advanced age of the patients, their 
significant co-existent morbidities and most importantly, the severity of the chronic 
morbidity associated with continuous hormone therapy.  These are well described and 
include anaemia, osteoporosis, impotence, cognitive functional effects, gynaecomastia, 
muscle atrophy, depression, dyslipidaemias and generalized lethargy [29-31]. This is 
the background to modern standards of care using endocrine therapy in prostate 
cancer. Continuous hormone therapy is the standard of care only in patients with 
metastatic and poor risk locally advanced disease.  
 
It is now nearly 20 years since the first attempts were made to diminish side effects of 
continuous therapy by giving pulsed endocrine treatments for long enough to normalize 
symptoms and signs of disease activity.  The first series published by Klotz et al 
described the use pulsed stilboestrol therapy for advanced prostate cancer with 
improved side effects [32]. This prompted further clinical and laboratory experiments to 
try and establish a scientific rationale for this type of treatment.  
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Work by Bruchovsky et al and Sato et al with mice models demonstrated that by 
castrating the animals and administering pulses of testosterone the onset of androgen 
independence was delayed and those receiving pulses of testosterone survived longer. 
[33].  
 
During the past decade this preclinical evidence has prompted several phase 2 clinical 
studies of intermittent hormone therapy, though as table 1 shows, there has been 
considerable variation in approach.  Initially treatment was with MAB for 6-9 months 
depending on the time to get PSA below 4.  With the reports casting doubt on the 
scientific rationale for MAB, some groups used LHRH monotherapy with no immediate 
worsening of results. Reports of excess non-cancer deaths after continuous anti-
androgen monotherapy prompted one group to explore intermittent therapy with this 
agent [35] even though the relatively elevated testosterone levels induced by these 
agents might have been expected to accelerate re-growth of cancer in such patients.  
Surprisingly this did not happen, though the authors did seem to report a higher rate of 
progression to androgen resistance. 
 
The results that have emerged from one of the three currently ongoing phase three 
clinical trials [11;36] generated the impetus to set up this meta-analysis. This trial, by the 
Southern European Uro-Oncology group (SEUG) which used LHRH and the anti-
androgen cyproterone acetate to treat metastatic and locally advanced disease patients, 
is the largest that has been recruited to date. With 626 patients they showed 
equivalence between continuous and intermittent treatment for disease progression and 
prostate cancer specific deaths with 8 years follow up.  Two observations of 
considerable importance emerged.  Firstly the authors had only used 3 months of 
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therapy before stopping treatment in the IHT arm and secondly they were able to 
demonstrate improved outcome in those achieving PSA less than 1.   
 
The results of our univariate and multivariate modeling are in agreement with the 
findings of the SEUG trial and confirm that stopping treatment in patients that achieve a 
good PSA response at 3 months is not deleterious to survival. Initial PSA and PSA nadir 
are consistent independent predictors of duration of remission. This observation does 
not of course exclude the longstanding critique of IHT, i.e. that the time off treatment is 
entirely due to the slowness of recovery of circulating testosterone. Studies have 
demonstrated that 90% of patients who have been treated with 3 months LHRH recover 
a normal testosterone within 18 weeks[37].  In the SEUG trial the majority of sexually 
active men in the intermittent arm recovered potency. These factors suggest that 
persistent low testosterone is not the explanation of the prolonged remission period.   
 
That monotherapy with anti-androgen alone was significantly less effective than 
Maximal androgen blockade or LHRH alone in groups 1 and 3 suggests that for the time 
being MAB or LHRH alone should be the standard for IHT trials. However, the 
surprising finding of increased survival in patients on anti-androgen monotherapy, might 
justify the use of these better tolerated drugs in specific subsets of prostate cancer 
patients, particularly those with biochemical recurrence after radiotherapy/prostatectomy 
[38].  
 
Using our dataset multivariate models which predicted time off treatment in all patient 
groups to a highly significant degree were generated. A model to predict the 
development of AIPC and overall survival could only be generated for group 3 (those 
with metastatic disease) as development of AIPC and death were too rare in the other 
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groups. This indicates the long follow up required to demonstrate differences in 
AIPC/death in this patient group.  
 
Table 4 demonstrates the association between time off treatment in the first cycle and 
time to develop AIPC (p<0.0001) and with time to death (not disease specific 
p<0.0001). Those with off periods of greater than 2 or 3 years or in the first cycle survive 
longer and develop androgen independent prostate cancer later than those with shorter 
duration off treatment. This might be used as an early indicator of treatment success in 
trials and might be used to demonstrate the effectiveness of different treatment 
protocols (with more or less patients staying off treatment for at least two or three years 
depending on treatment efficacy) prior to demonstration of a difference in the rate of 
androgen independence or death for which duration of follow up would be extensive.  
 
One concern about use of time off treatment as an indicator of treatment success for 
clinical trials, is that PSA rise being time dependant, it might be that the duration of a 
remission period is only dependant upon the level to which PSA is allowed to rise before 
retreatment. In table 5 it is demonstrated that this is not so. No significant difference 
was seen between the duration of preceding remission periods when patients were 
grouped according to the PSA at which their treatment was restarted. 
 
The collated dataset lends itself to analysis to evaluate which features of an IHT 
protocol render it most successful (within the bounds of those protocols already in use). 
The results will be useful in designing clinical trials examining the optimal use of IHT. 
 
 11 
In order to better understand the biology of prostate cancer with hormone treatment and 
to evaluate the safety and efficacy of the variety of IHT protocols that are included in 
this study randomized controlled clinical trials are required.   
 
A recent Editorial in the Journal of Urology describes how prostate cancer is overtreated 
at present [39]. The observations made in this meta-analysis taken with the SEUG trial 
data provide support for identifying cases not requiring radical treatment and as 
exploring the use of 3 months MAB as an alternate to watchful waiting.  
 
Conclusions 
The increasing evidence from randomized trials that IHT is safe is supported by this 
meta-analysis. Our data suggest that it is possible to curtail treatment duration to 3 
months (in all patients except those with metastatic disease). A randomized controlled 
trial to see if this bears out prospectively is indicated. Given the low toxicity of such a 
course of treatment the next priority for a trial must be in patients not willing to accept 
the anaemia, bone thinning, impotence and changes in cognitive function associated 
with continuous therapy, ie those for whom watchful waiting would be suitable. Outcome 
should include assessment of side effects. Testosterone levels should be monitored. 
 
Limitations 
Medication type has been grouped despite acknowledging differences in different 
individual drugs and doses used. Testosterone levels are not analysed. 
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Table 1.  
 
Reference 
author 
Origin N Type of 
disease 
Type of 
treatment 
PSA nadir for 
adequate 
response 
Restart 
PSA 
% off at 2 
years 
Strum [20] California, 
USA 
53 L & A MAB  <0.05 >5 13 
Forman 
[17;40] 
Michigan, 
USA 
104 L, R & A MAB /  
mono 
<4 >10 39 
Malone [41] Ottawa, 
Canada 
86 L, R & A MAB /  
mono 
<4 >10 20 
Small [42] San 
Francisco, 
USA 
53 L & R MAB /  
mono 
<4 if no prev 
Rx <0.1 post 
RT/RP  
>10  
Or >50% 
baseline  
36 
Zerbib [43] Paris, 
France 
160 L, R & A MAB /  
mono 
<1 no prev Rx 
<0.05 post RP 
<4 post RT 
>10  
>4 post 
RP  
11 
Goldenberg 
[44] 
Vancouver, 
Canada 
101 L, R & A MAB /  
mono 
<2 >10  
>4 post 
RP 
17 
Spry  Perth, 
Australia 
239 L, R & A MAB Variable- all 9 
months MAB 
>20 31 
Oliver [17] London 
U.K. 
125 L, R & A MAB /  
mono 
<4 >20  30 
Prapotnich 
[45] 
Paris, 
France 
411 L, R & A MAB <4 >20 40 
Albrecht 
[46] 
Europe 114 A  MAB <20 or  
<20% initial 
>20 or 
>1.5*nadir 
6  
(at 1 year) 
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Table 2.  
 
 
Group 1 Localized 
disease (n=517) 
 
Group 2 
Biochemical 
recurrence (N0M0) 
(n=563) 
Group 3 
Metastatic disease 
(n=366) 
Overall survival at 5 years 90% 86% 68% 
Patients off treatment at 2 
years 29% 33% 16% 
Patients with AIPC at 5 
years 10% 17% 41% 
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Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Time off treatment Androgen resistance Overall survival 
Group 1 Group 2 Group 3 Group 1 Group 2 Group 3 Group 1 Group 2 Group 3 
T stage 1/2 - - - - - - - - - 
3/4 - 1.48 *** - - - - 1.85 ** - - 
Initial PSA <10 - - - - - - - - - 
10-75 1.47 ** 1.44 *** 1.77 ** 6.42 *** 1.62 * 5.52 ** 2.7 ** - - 
>75 1.41** - 1.66 *** 2.65 ** - 3.26 ** - - 2.33 *** 
Grade 2-7 - - - - - - - - - 
8-10 - 1.36  ** - - - - - - - 
PSA Nadir <1 - - - - - - - - - 
1-2 1.68 *** - - - - 2.12 ** - - 2.12 ** 
>2 - 1.77 *** 1.43 *** - - - - - - 
Type of 
medication 
MAB - - - - - - - - - 
a/a 2.14 * 2.59 * - 3.78** - - - - - 
LHRH - - - 4.41 ** - - - - - 
Duration on 
treatment 
≤ 4 months - - - - - - - - 1.86 * 
4-8 months - - - 4.44 * - - - - 2.83 *** 
≥ 8 months - - - 6.05 ** - - - - - 
Age <65 - 1.55 *** - - - - - - - 
≥65 - - - - - - - - - 
PSA restart 
threshold 
≤ 15 - - - - - - - - - 
>15 - - -  - 1.33 * - - 1.65 * 
Prev Rx None - - - - - - - - - 
RT &/or RP - - 2.2 *** - - - - - - 
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Figure 1a                                                       Figure 1b 
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Figure 2. 
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Table 4.  
 
Excluding<2 years 
Off treatment 
at 2 years 
Androgen Independence Overall Survival 
HR HR 95%c.i.  
No 12.12 5.93 – 24.74 2.24 1.56-3.23 
Yes ref ref 
 Chi squared = 97.77 
P <0.0001 
Chi squared = 21.49 
P < 0.0001 
*Off 
treatment at 
2 years 
Androgen Independence Overall Survival 
HR 95%c.i. HR 95%c.i. 
No 9.5 4.6 – 19.5 2.2 1.45 – 3.2 
Yes ref ref 
 Chi squared = 68.33 
P <0.0001 
Chi squared =  15.76 
P <0.0001 
*Off 
treatment at 
3 years 
Androgen Independence Overall Survival 
HR 95%c.i. HR 95%c.i. 
No 6.82 2.96-15.72 2.93 1.68 – 5.11 
Yes ref ref 
 Chi squared = 34.18 
P <0.0001 
Chi squared =  17.73 
P <0.0001 
 
 
 
 
 
 
 
Table 5.  
 
Duration of remission 
greater than the median for 
all patients 
PSA level prompting restarting of hormone 
therapy 
  
<10 10-20 >20 
No 257 345 45 
Yes 232 367 41 
Total 489 712 86 
Median for group (months) 11.6 12.3 12.0 
Pearson,  chi2(2) =   2.1059   P= 0.349 
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Appendix 1 
 Group 1 Group 2 Group 3 
Factor n 
% 
Off 
treatment 
 
HR 95% c.i. P n 
% 
Off 
treatment 
 
HR 95% c.i. P n 
% 
Off 
treatment 
 
HR 95% c.i. P 
T stage 
1 or 2 251 29   
0.8 
212 37   
0.0008 
54 47   
0.9 3 or 4 187 29 1.04 0.83 - 1.20 181 25 1.48 1.18 – 1.87 72 40 1.02 0.68 – 1.54 
missing 37 26   113 42   185 28   
Initial PSA 
< 10 91 41   
0.0003 
(Trend) 
 
175 41   
0.05 
(Trend) 
23 70   
<0.0001 
(Trend) 
10-75 295 25 1.47 1.11 – 1.95 287 27 1.44 1.14 – 1.92 163 39 1.77 1.04 – 3.03 
> 75 60 23 1.41 1.16 – 1.72 21 56 0.95 0.73 – 1.24 116 20 1.66 1.26 – 2.18 
missing 71 42   23 33   9 33   
Gleason grade 
2-7 165 30   
0.05 
 
185 38   
0.008 
53 51   
0.2 > 7 237 28 1.26 0.99 – 1.58 249 29 1.36 1.08 – 1.71 133 43 1.25 0.86 – 1.8 
missing 67 29   72 38   125 17   
Type of 
medication 
antiandrogen 68 11 2.14 1.23 – 3.24 0.005 77 10 2.59 1.83 – 3.72 0.0001 17 0 1.16 0.88 – 1.36 0.3 
LHRH 39 31 1.2 0.96 – 1.45 0.7 93 38 1.02 0.93-1.10 0.9 12 39 1.3 0.77 – 1.82 0.7 
MAB 404
 
32    389 38    334 15    
missing 0 -    6 42    23 26    
Duration on 
treatment 
< 4 months 148 35   
0.3 
(Trend) 
 
125 42   
0.08 
(Trend) 
75 32 1.35 1 - 1.83  
0.06 
(Trend) 
 
 
4-8 months 102 24 1.26 0.93-1.67 169 28 1.36 1.03-1.81 81 27 1.17 1 - 1.82 
>  8 months 219 27 1.06 0.88-1.45 211 32 1.1 0.93-1.60 151 39   
missing 0 -   1 100   1 0   
PSA nadir 
< 1 273 33   
0.003 
(Trend) 
 
395 35   
0.049 
(Trend) 
 
180 41   <0.0001 
(Trend) 
 
 
1-2 67 15 1.68 1.24-2.28 32 40 0.85 0.53 - 1.35 30 23 1.36 0.89 – 2.08 
> 2 29 30 1.45 0.92-2.27 18 8 3.63 1.75 - 7.53 49 21 1.43 1.20 – 1.71 
missing 100 25   61 25   32 31   
Age 
≤ 65 70 23 1.16 0.88 – 1.56 
0.3 
145 25 1.55 1.25 - 1.94 
0.0001 
102 29 1.19 0.91 – 1.55 
0.2 > 65 393 30   353 37   200 38   
missing 6 42   8 43   9 11   
Previous 
treatment 
none - - - - 
- 
- - - - 
- 
281 31 2.2 1.39-3.48 
0.0002 RP and/or RT - - - - - - - - 30 57   
missing - - - - - - - - - - - - 
PSA restart 
threshold 
≤15 190 29 1.03 0.82-1.28 
0.8 
236 30 1.12 0.91-1.38 
0.3 
85 32   
0.5 >15 294 28   280 35   271 33 1.1 0.83-1.46 
missing 33 33   42 47   10 27   
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Appendix 2 
 Time Off treatment Androgen Independence Overall Survival 
Factor Group 1 Group 2 Group 3 Group 1 Group 2 Group 3 Group 1 Group 2 Group 3 HR (chi2) HR (chi2) HR (chi2) HR (chi2) HR (chi2) HR (chi2) HR (chi2) HR (chi2) HR (chi2) 
T stage  1-2 NS Ref NS NS NS NS Ref NS NS 
3-4 1.48 (11.34) *** 1.85 (3.31)** 
Initial PSA  
<10 Ref Ref Ref Ref Ref Ref Ref 
NS 
Ref 
10-75 1.47 (7.8) ** 1.44 (9.9) *** 1.77 (5.06)** 6.42 (5.55)*** 1.62 (2.4)* 5.52 (5.09)** 2.70 (4.21)** NS 
>75 1.41 (11.15)*** 
 
NS 1.66 (16.12)*** 2.65 (3.96)** NS 3.26 (5.23)** 
 
NS 2.33 (9.42)*** 
Gleason 
grade  
≤ 7 
NS 
Ref 
NS NS NS NS NS NS NS 
> 7 1.36(7.15)** 
Type of 
medication 
MAB Ref Ref 
NS 
Ref 
NS NS NS 
2.28 (6.12)* 
NS LHRH alone NS NS 4.41 (5.82)* 4.28 (13.68)*** 
antiandrogen 2.14 (19.11)*** 2.59 (39.31)*** 3.78 (4.84)* Ref 
Duration of 
treatment  
≤ 4 months 
NS NS NS 
Ref 
NS NS NS NS 
1.86 (2.89)* 
4-8 months 4.44 (2.4)* 2.83 (13.54)*** 
≥ 8 months 6.05 (5.1)** Ref 
PSA nadir 
< 1 Ref Ref Ref 
NS NS 
Ref 
NS NS 
Ref 
1-2 1.68 (10.87)*** 
 
NS NS 2.12 (6.98)** 2.12 (6.98)** 
>2 NS 1.77 (10.69)*** 1.43 (13.86)*** NS NS 
Age  < 65 NS 
1.55 (14.55)*** 
NS NS NS NS NS NS NS 
≥ 65 Ref 
Previous 
treatment  
none N/A N/A Ref N/A N/A NS N/A N/A NS 
RP &/or RT  2.2(14.04)*** 
PSA restart 
threshold 
≤15 
NS NS NS NS NS 
Ref 
NS NS 
Ref 
>15 1.33 (4.11)* 1.65 (4.08)* 
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Appendix 3 
 N Chi2 Change Chi2 
Group 1- Time off treatment 
IP 446 9.67 9.67 
IP+IPm 464 12.31  
IP+IPm+MAB 464 29.92 17.61 
IP+IPm+MAB+MABm 369 37.5  
IP+IPm+MAB+MABm+PN 369 46.95 9.45 
IP+IPm+MAB+MABm+PN+PNm 402 38.84  
IP+IPm+MAB+MABm+PN+PNm+G 402 46.05 7.21 
Group 2- Time off treatment 
MAB 501 13.98 13.98 
MAB+MABm  497 14.58  
MAB+MABm+A 497 29.06 14.48 
MAB+MABm+A+Am 482 25.09  
MAB+MABm+A+Am+IP 482 31.46 6.37 
Group 3- Time off treatment 
IP 302 23.86 23.86 
IP+IPm 311 23.89  
IP+IPm+PrevRx 311 35.6 11.71 
IP+IPm+PrevRx +PN 259 39.05 4.55 
 N Chi2 Change Chi2 
Group 3- Androgen Independence 
IP 355 24.48 24.48 
IP+IPm 346 27.23  
IP+IPm+RT 346 30.07 5.59 
 N Chi2 Change Chi2 
Group 3- Overall Survival 
ON 329 13.72 13.72 
ON+ONm 280 10.39  
ON+ONm+PN 280 17.09 3.37 
ON+ONm+PN+PNm 277 17.04  
ON+ONm+PN+PNm+IP 277 23.27 6.18 
ON+ONm+PN+PNm+IP+IPm 275 24.86  
ON+ONm+PN+PNm+IP+IPm+MAB 275 30.42 7.15 
ON+ONm+PN+PNm+IP+IPm+MAB+MABm 267 28.16  
ON+ONm+PN+PNm+IP+IPm+MAB+MABm+RT 267 37.03 6.61 
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Table 1. Showing the origins, characteristics and basic protocol for IHT from the 
different contributing authors. 
(L= localized disease primary treatment, R= biochemical recurrence after RP/RT 
localized , A= advanced disease) 
 
Table 2. Overall survival, time off treatment and time to developing AIPC for all patients 
by group. 
 
Table 3. Summary of risk factors as predictors of outcome in univariate analysis by 
group. 
 
Figure 1a and 1b. Kaplan Meier survival analysis to show the overall survival by group 
and the effect of Initial PSA on the duration of remission in patients with localised 
disease treated primarily with hormone therapy (group 1) 
 
Figure 2. Graphs to demonstrate the relative contributions of individual factors in 
multivariate models predicting treatment outcomes.   
 
Table 4. Time off Rx as a surrogate measure for AIPC and overall survival. (For data 
marked *, In order to avoid a length time bias those patients who have neither been off 
treatment for the duration of interest- 2 or 3 years, or restarted treatment are excluded). 
 
Table 5. Analysis of association between duration of preceeding remission and PSA 
threshold at which treatment is restarted. 
 
Appendices  
 
Appendix 1. Univariate analysis of risk factors for being off treatment at 2 years (group 1 
and 2) or 1 year (group 3)  
 
Appendix 2.  Significance of factors predicting time off treatment in the different clinical 
groups by univariate analysis (*=p<0.05, **=p<0.01, ***=p<0.001) 
 
Appendix 3. Multivariate model for each group predicting duration of remission (time off 
treatment) based on initial PSA (IP), PSA nadir <1 (PN) reached, type of hormone 
therapy (MABvs monotherapy), tumour gleason grade(G), T stage (T), Age (A), 
Previous treatment (PrevRx), Restart PSA Threshold (RT) 
 
